Hematological Malignancies

PFS: On study vs. last prior therapy

Median PFS (months) On study: 11.0 Last prior therapy: 4.6

PFS (%)

Time from start of idelalisib (months)

125 125

60 40

33 14

22

12

4 2

Patients at risk, n

9

5

1